Search Results | Blood | American Society of Hematology

1-20 of 54

2 3

Sort by

Sort Order Select

Journal Articles

Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

Blood (2020) 136 (Supplement 1): 10–11.

DOI: https://doi.org/10.1182/blood-2020-137528

Published: 2020

Journal Articles

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Blood (2020) 136 (Supplement 1): 11–13.

DOI: https://doi.org/10.1182/blood-2020-136539

Published: 2020

Journal Articles

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Felix Korell, MD, Thomas Luft, MD, PhD, Michael Schmitt, MD, Sascha Dietrich, MD, Anita Schmitt, MD, Carsten Mueller-Tidow, MD, Peter Dreger, MD

Blood (2020) 136 (Supplement 1): 11–12.

DOI: https://doi.org/10.1182/blood-2020-139615

Published: 2020

Journal Articles

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Nora Liebers, Peter-Martin Bruch, Agnes Gambietz, Holly Giles, BA, Junyan Lu, PhD, Mareike Knoll, Carolin Kolb, Peter Dreger, Carsten Mueller-Tidow, MD, Wolfgang Huber, PhD, Axel Benner, Thorsten Zenz, MD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 376.

DOI: https://doi.org/10.1182/blood-2019-125324

Published: 2019

Journal Articles

Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia

Laura Llaó Cid, M.Sc, Philipp M Rößner, MD, Ekaterina Lupar, PhD, Bola S Hanna, PhD, Jérôme Paggetti, PhD, Etienne Moussay, PhD, Dolors Colomer, PhD, Sascha Dietrich, MD, Stephan Stilgenbauer, MD, Ana Izcue, PhD, Martina Seiffert, PhD

Blood (2019) 134 (Supplement_1): 4288.

DOI: https://doi.org/10.1182/blood-2019-128465

Published: 2019

Journal Articles

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, MD, Thomas Luft, MD PhD, Andrea Bondong, Ute Hegenbart, MD, Julia Meissner, MD, Nora Liebers, Michael Schmitt, MD, Carsten Mueller-Tidow, MD, Peter Dreger

Blood (2019) 134 (Supplement_1): 3328.

DOI: https://doi.org/10.1182/blood-2019-128352

Published: 2019

Journal Articles

Systematic Investigation of Microenvironmental Drug Resistance Mechanisms in Chronic Lymphocytic Leukemia

Peter-Martin Bruch, Holly Giles, BA, Carolin Kolb, Sophie Rabe, MSc, Tobias Roider, MD, Mareike Knoll, Mark Kriegsmann, MD, Katharina Kriegsmann, MD, Christiane Zgorzelski, Sebastian Scheinost, Lena Wagner, Carsten Müller-Tidow, MD, Thorsten Zenz, MD, Wolfgang Huber, PhD, Sascha Dietrich, MD

Blood (2019) 134 (Supplement_1): 3363.

DOI: https://doi.org/10.1182/blood-2019-128392

Published: 2019

Journal Articles

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Thorsten Zenz, MD, Almut Luetge, Junyan Lu, PhD, Huellein Jennifer, PhD, Sascha Dietrich, MD, Leopold Sellner, MD, Wolfgang Huber, PhD

Blood (2019) 134 (Supplement_1): 1742.

DOI: https://doi.org/10.1182/blood-2019-126388

Published: 2019

Journal Articles

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness

Blood (2019) 134 (10): 836–840.

DOI: https://doi.org/10.1182/blood.2019000080

Published: 2019

Includes: Supplemental data

Journal Articles

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Blood (2019) 134 (6): 534–547.

DOI: https://doi.org/10.1182/blood.2018881029

Published: 2019

Includes: Supplemental data

Journal Articles

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

Robert J. Kreitman, MD, Philippe Moreau, Martin Hutchings, MD, Anas Gazzah, MD, Jean-Yves Blay, MD PhD, Zev A. Wainberg, MD, Alexander Stein, MD, Sascha Dietrich, MD, Maja J.A. de Jonge, MD, Wolfgang Willenbacher, MD, Jacques De Greve, MD, Evgeny Arons, PhD, Farhad Ravandi, MD, Fatima Rangwala, Paul Burgess, Bijoyesh Mookerjee, Vivek Subbiah, MD

Blood (2018) 132 (Supplement 1): 391.

DOI: https://doi.org/10.1182/blood-2018-99-113135

Published: 2018

Journal Articles

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Sophie Rabe, MSc, Eva Schitter, Tobias Roider, Peter-Martin Bruch, Carolin Kolb, Marta Stolarczyk, Jennifer Hüllein, Junyan Lu, Christof von Kalle, Christoph Lutz, Peter Dreger, Carsten Mueller-Tidow, Thorsten Zenz, MD, Wolfgang Huber, Sascha Dietrich, MD

Blood (2018) 132 (Supplement 1): 262.

DOI: https://doi.org/10.1182/blood-2018-99-116053

Published: 2018

Journal Articles

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

Francesca Guidetti, Alessio Bruscaggin, PhD, Marco Frigeni, MD, Valeria Spina, PhD, Lodovico Terzi di Bergamo, Adalgisa Condoluci, MD, Gabriela Forestieri, Francesco Bertoni, MD, Luciano Cascione, PhD, Manuela Mollejo, Véronique Meignin, Alexandra Traverse-Glehen, MD PhD, Julia T Geyer, MD, Alessandro Broccoli, Alessandra Tucci, Silvia Bea, Renzo Boldorini, Gustavo Tapia, Antonino Maiorana, Maria Gomes da Silva, MD, Juan F. Garcia, Felicitas Hitz, Michele Merli, MD, Giorgio A. Vanini, Urban Novak, Francesco Piazza, Stefano Pizzolitto, Sascha Dietrich, Liliana Devizzi, Marco Ladetto, Maurilio Ponzoni, MD, Alessandro Rambaldi, MD, Paolo Corradini, Corrado Tarella, Elisa Santambrogio, Umberto Vitolo, Francesco Zaja, Francesco Passamonti, MD, Alexandar Tzankov, Sergio Cogliatti, Carlos Montalban, Roberto Marasca, MD, Laurence de Leval, MD, Carlo Visco, Maria Joao Baptista, PhD PharmD, Vincenzo Canzonieri, Estella Matutes, Fabio Facchetti, Marco Paulli, Elias Campo, David Oscier, Elena Sabattini, Pier Luigi Zinzani, MD, Govind Bhagat, Stefano A. Pileri, MD PhD, Giorgio Inghirami, MD, Gianluca Gaidano, MD PhD, Gilles Salles, MD PhD, Catherine Thieblemont, MD, Miguel A. Piris, Franco Cavalli, MD, Emanuele Zucca, Luca Arcaini, MD, Davide Rossi, MD PhD

Blood (2018) 132 (Supplement 1): 922.

DOI: https://doi.org/10.1182/blood-2018-99-115958

Published: 2018

Journal Articles

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Blood (2017) 130 (Supplement 1): 2994.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2994.2994

Published: 2017

Journal Articles

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

Brief Report

Blood (2017) 130 (14): 1644–1648.

DOI: https://doi.org/10.1182/blood-2017-01-765107

Published: 2017

Includes: Supplemental data

Journal Articles

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Clinical Trials & Observations

Isabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, Sebastian Böttcher, Matthias Zeis, Michael Stadler, Jörg Bittenbring, Lutz Uharek, Christof Scheid, Ute Hegenbart, Anthony Ho, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Döhner, Peter Dreger

Blood (2017) 130 (12): 1477–1480.

DOI: https://doi.org/10.1182/blood-2017-04-775841

Published: 2017

Includes: Supplemental data

Journal Articles

Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial

Isabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, Sebastian Böttcher, Matthias Ritgen, Donald Bunjes, Matthias Zeis, Michael Stadler, MD, Joerg Thomas Bittenbring, MD, Ute Hegenbart, Michael Hallek, Michael Kneba, Norbert Schmitz, MD, PhD, Hartmut Döhner, MD, Peter Dreger, MD

Blood (2016) 128 (22): 682.

DOI: https://doi.org/10.1182/blood.V128.22.682.682

Published: 2016

Journal Articles

A Distributed International Patient Data Registry for Hairy Cell Leukemia

Leslie A. Andritsos, MD, Michael R. Grever, MD, Mirela Anghelina, MD, Claire E Dearden, MD FRCP, FRCPath, Monica Else, MA, MSc, James S. Blachly, MD, Omkar Lele, MS, MBA, Farhad Ravandi, MD, Clive S Zent, MD, James B. Johnston, MD FRCP, Versha Banerji, MD FRCP, Francesco Forconi, MD DM, PhD FRCPath, Anthony D. Ho, MD, Thorsten Zenz, Sascha Dietrich, Judit Demeter, MD PhD, Jacqueline C. Barrientos, MD, Jan A. Burger, MD PhD, Timothy G. Call, MD, Nicholas Chiorazzi, MD, Daniel J. DeAngelo, MD PhD, Julio Delgado, MD, Andrei Fagarasanu, MD PhD, Brunangelo Falini, Alessandro Gozzetti, MD, Jeffrey Jones, MD MPH, Gunnar Juliusson, MD, Eric H. Kraut, MD, Robert J. Kreitman, MD, Loree Larratt, MD, Francesco Lauria, MD, Gerard Lozanski, MD, Emili Montserrat, MD, Sameer A. Parikh, MD, Jae H. Park, MD, Aaron Polliack, MD, Graeme R. Quest, MD MSc, Kanti R. Rai, MD, Tadeusz Robak, MD PhD, Alan Saven, MD, Tamar Tadmor, MD, Martin S. Tallman, MD, Constantine S. Tam, MBBS, Enrico Tiacci, MD, Xavier Troussard, MD PhD, Omar Abdel-Wahab, MD, Pier Luigi Zinzani, MD, PhD, Christopher Heckler, BS, MBA, Philip R.O. Payne, PhD

Blood (2016) 128 (22): 5986.

DOI: https://doi.org/10.1182/blood.V128.22.5986.5986

Published: 2016

Journal Articles

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Clinical Trials & Observations

Blood (2016) 127 (23): 2847–2855.

DOI: https://doi.org/10.1182/blood-2015-11-680074

Published: 2016

Includes: Supplemental data

Journal Articles

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Leopold Sellner, MD, Peter Dreger, MD, Max Schlitt, Henrik Knecht, Dietrich Herrmann, Thomas Reigl, Adam Krejci, Vojtech Bystry, Nikos Darzentas, Michael Rieger, MD, Sascha Dietrich, MD, Thorsten Zenz, MD, Anthony D. Ho, MD, Michael Kneba, Monika Brueggemann

Blood (2015) 126 (23): 3159.

DOI: https://doi.org/10.1182/blood.V126.23.3159.3159

Published: 2015

2 3

NARROW

Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Ex-Vivo Drug Response Profiling for Tailoring Treatment in Hematologic Malignancies: The Prospective Non-Interventional SMART-Trial

Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Systematic Investigation of Microenvironmental Drug Resistance Mechanisms in Chronic Lymphocytic Leukemia

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)

The Influence of the Bone Marrow Niche on Drug Response Phenotypes of Blood Cancers

Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial

A Distributed International Patient Data Registry for Hairy Cell Leukemia

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only